Tanfanercept - HanAll Biopharma
Alternative Names: Anti-TNF-alpha protein - HanAll Biopharma; HBM-9036; HL 036; HL-036337; HL-189 - HanAll Biopharma; TNF-alpha blocker - HanAll BiopharmaLatest Information Update: 10 Jun 2024
Price :
$50 *
At a glance
- Originator HanAll Biopharma
- Developer Daewoong Pharmaceutical; HanAll Biopharma; Harbour BioMed; Unknown
- Class Anti-inflammatories; Biobetters; Eye disorder therapies; Recombinant proteins
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Dry eyes
- Preclinical Uveitis
- No development reported Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 31 May 2024 HanAll Biopharma suspends the phase III VELOS-4 trial in Dry eyes in USA (Opthalmic) due to logistical issue(NCT06400589)
- 01 May 2024 HanAll Biopharma initiates a phase III VELOS-4 trial for Dry eyes in USA (Opthalmic), before May 2024 (NCT06400589)
- 21 Mar 2024 HanAll Biopharma and Daewoong Pharmaceutical successfully conclude discussions with the US FDA to finalize phase 3 VELOS-4 trial design and development plan for Dry eyes, in 2H of 2023